APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibodies for Plaque Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Monoclonal Antibodies for Plaque Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025191 pages

Choose your research edition.

Industry ResearchMonoclonal Antibodies for Plaque Psoriasis Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibodies for Plaque Psoriasis Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibodies for Plaque Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibodies for Plaque Psoriasis Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibodies for Plaque Psoriasis Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Monoclonal Antibodies for Plaque Psoriasis market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Monoclonal Antibodies for Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Monoclonal Antibodies for Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monoclonal Antibodies for Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Monoclonal Antibodies for Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Monoclonal Antibodies for Plaque Psoriasis include AbbVie, Inc., Almirall SA, Bausch Health Cos., Inc, Biocon Ltd., Janssen Biotech, Inc., Sun Pharmaceutical Industries Ltd., UCB, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd and Eli Lilly & Co., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Monoclonal Antibodies for Plaque Psoriasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Monoclonal Antibodies for Plaque Psoriasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Monoclonal Antibodies for Plaque Psoriasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Monoclonal Antibodies for Plaque Psoriasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Monoclonal Antibodies for Plaque Psoriasis Segment by Company

AbbVie, Inc.

Almirall SA

Bausch Health Cos., Inc

Biocon Ltd.

Janssen Biotech, Inc.

Sun Pharmaceutical Industries Ltd.

UCB, Inc.

Jiangsu Hengrui Pharmaceuticals Co., Ltd

Eli Lilly & Co.

Novartis AG

Chongqing Genrix Biopharmaceutical Co., Ltd

Monoclonal Antibodies for Plaque Psoriasis Segment by Type

5-100 mg/mL

100-200 mg/mL

Monoclonal Antibodies for Plaque Psoriasis Segment by Application

Hospital

Clinic

Others

Monoclonal Antibodies for Plaque Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibodies for Plaque Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibodies for Plaque Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibodies for Plaque Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Monoclonal Antibodies for Plaque Psoriasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Monoclonal Antibodies for Plaque Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Monoclonal Antibodies for Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Monoclonal Antibodies for Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Monoclonal Antibodies for Plaque Psoriasis Industry Trends Table 2. Monoclonal Antibodies for Plaque Psoriasis Industry Drivers Table 3. Monoclonal Antibodies for Plaque Psoriasis Industry Opportunities and Challenges Table 4. Monoclonal Antibodies for Plaque Psoriasis Industry Restraints Table 5. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Manufacturers Table 9. Global Monoclonal Antibodies for Plaque Psoriasis Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Monoclonal Antibodies for Plaque Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Monoclonal Antibodies for Plaque Psoriasis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Monoclonal Antibodies for Plaque Psoriasis Manufacturers, Product Type & Application Table 13. Global Monoclonal Antibodies for Plaque Psoriasis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Monoclonal Antibodies for Plaque Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 5-100 mg/mL Table 17. Major Manufacturers of 100-200 mg/mL Table 18. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2021-2026) & (K Units) Table 20. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2027-2032) & (K Units) Table 21. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Type (2021-2026) Table 22. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Type (2027-2032) Table 23. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2021-2026) & (K Units) Table 25. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2027-2032) & (K Units) Table 26. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Type (2021-2026) Table 27. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Others Table 31. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2021-2026) & (K Units) Table 33. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2027-2032) & (K Units) Table 34. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Application (2021-2026) Table 35. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Application (2027-2032) Table 36. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2021-2026) & (K Units) Table 38. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2027-2032) & (K Units) Table 39. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Application (2021-2026) Table 40. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Application (2027-2032) Table 41. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region (2021-2026) & (K Units) Table 43. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Region (2021-2026) Table 44. Global Monoclonal Antibodies for Plaque Psoriasis Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Monoclonal Antibodies for Plaque Psoriasis Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Monoclonal Antibodies for Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 48. North America Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 49. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 51. Europe Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 58. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Region (2021-2026) Table 62. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Region (2027-2032) Table 63. AbbVie, Inc. Company Information Table 64. AbbVie, Inc. Business Overview Table 65. AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 67. AbbVie, Inc. Recent Development Table 68. Almirall SA Company Information Table 69. Almirall SA Business Overview Table 70. Almirall SA Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Almirall SA Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 72. Almirall SA Recent Development Table 73. Bausch Health Cos., Inc Company Information Table 74. Bausch Health Cos., Inc Business Overview Table 75. Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 77. Bausch Health Cos., Inc Recent Development Table 78. Biocon Ltd. Company Information Table 79. Biocon Ltd. Business Overview Table 80. Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 82. Biocon Ltd. Recent Development Table 83. Janssen Biotech, Inc. Company Information Table 84. Janssen Biotech, Inc. Business Overview Table 85. Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 87. Janssen Biotech, Inc. Recent Development Table 88. Sun Pharmaceutical Industries Ltd. Company Information Table 89. Sun Pharmaceutical Industries Ltd. Business Overview Table 90. Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 92. Sun Pharmaceutical Industries Ltd. Recent Development Table 93. UCB, Inc. Company Information Table 94. UCB, Inc. Business Overview Table 95. UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 97. UCB, Inc. Recent Development Table 98. Jiangsu Hengrui Pharmaceuticals Co., Ltd Company Information Table 99. Jiangsu Hengrui Pharmaceuticals Co., Ltd Business Overview Table 100. Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 102. Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Development Table 103. Eli Lilly & Co. Company Information Table 104. Eli Lilly & Co. Business Overview Table 105. Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 107. Eli Lilly & Co. Recent Development Table 108. Novartis AG Company Information Table 109. Novartis AG Business Overview Table 110. Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Novartis AG Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 112. Novartis AG Recent Development Table 113. Chongqing Genrix Biopharmaceutical Co., Ltd Company Information Table 114. Chongqing Genrix Biopharmaceutical Co., Ltd Business Overview Table 115. Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Portfolio Table 117. Chongqing Genrix Biopharmaceutical Co., Ltd Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Monoclonal Antibodies for Plaque Psoriasis Distributors List Table 121. Monoclonal Antibodies for Plaque Psoriasis Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Monoclonal Antibodies for Plaque Psoriasis Product Image Figure 2. Global Monoclonal Antibodies for Plaque Psoriasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monoclonal Antibodies for Plaque Psoriasis Market Size (2021-2032) & (US$ Million) Figure 4. Global Monoclonal Antibodies for Plaque Psoriasis Sales (2021-2032) & (K Units) Figure 5. Global Monoclonal Antibodies for Plaque Psoriasis Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Monoclonal Antibodies for Plaque Psoriasis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 5-100 mg/mL Image Figure 9. 100-200 mg/mL Image Figure 10. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Type (2021-2032) Figure 13. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Application (2021-2032) Figure 22. Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Application (2021-2032) Figure 25. North America Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 27. U.S. Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 32. Germany Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 39. China Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 47. Brazil Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Monoclonal Antibodies for Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Monoclonal Antibodies for Plaque Psoriasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Monoclonal Antibodies for Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Figure 58. North America Monoclonal Antibodies for Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Monoclonal Antibodies for Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Figure 60. Europe Monoclonal Antibodies for Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Monoclonal Antibodies for Plaque Psoriasis Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Monoclonal Antibodies for Plaque Psoriasis Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 5-100 mg/mL
  • 100-200 mg/mL
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • AbbVie, Inc.
  • Almirall SA
  • Bausch Health Cos., Inc
  • Biocon Ltd.
  • Janssen Biotech, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • UCB, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd
  • Eli Lilly & Co.
  • Novartis AG
  • Chongqing Genrix Biopharmaceutical Co., Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Monoclonal Antibodies for Plaque Psoriasis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Monoclonal Antibodies for Plaque Psoriasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Monoclonal Antibodies for Plaque Psoriasis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Monoclonal Antibodies for Plaque Psoriasis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Monoclonal Antibodies for Plaque Psoriasis Market Dynamics
  1. 2.1 Monoclonal Antibodies for Plaque Psoriasis Industry Trends
  2. 2.2 Monoclonal Antibodies for Plaque Psoriasis Industry Drivers
  3. 2.3 Monoclonal Antibodies for Plaque Psoriasis Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibodies for Plaque Psoriasis Industry Restraints
3 Monoclonal Antibodies for Plaque Psoriasis Market by Manufacturers
  1. 3.1 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Manufacturers (2021-2026)
  3. 3.3 Global Monoclonal Antibodies for Plaque Psoriasis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Monoclonal Antibodies for Plaque Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Monoclonal Antibodies for Plaque Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Monoclonal Antibodies for Plaque Psoriasis Manufacturers, Product Type & Application
  7. 3.7 Global Monoclonal Antibodies for Plaque Psoriasis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Monoclonal Antibodies for Plaque Psoriasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Monoclonal Antibodies for Plaque Psoriasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Monoclonal Antibodies for Plaque Psoriasis Tier 1, Tier 2, and Tier 3
4 Monoclonal Antibodies for Plaque Psoriasis Market by Type
  1. 4.1 Monoclonal Antibodies for Plaque Psoriasis Type Introduction
  2. 4.1.1 5-100 mg/mL
  3. 4.1.2 100-200 mg/mL
  4. 4.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type
  5. 4.2.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Type (2021-2032)
  7. 4.2.3 Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Type (2021-2032)
  8. 4.3 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type
  9. 4.3.1 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Type (2021-2032)
  11. 4.3.3 Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Type (2021-2032)
5 Monoclonal Antibodies for Plaque Psoriasis Market by Application
  1. 5.1 Monoclonal Antibodies for Plaque Psoriasis Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application
  6. 5.2.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Application (2021-2032)
  8. 5.2.3 Global Monoclonal Antibodies for Plaque Psoriasis Sales Market Share by Application (2021-2032)
  9. 5.3 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application
  10. 5.3.1 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Application (2021-2032)
  12. 5.3.3 Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Application (2021-2032)
6 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region
  1. 6.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region (2021-2032)
  3. 6.2.1 Global Monoclonal Antibodies for Plaque Psoriasis Sales by Region (2021-2026)
  4. 6.2.2 Global Monoclonal Antibodies for Plaque Psoriasis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Monoclonal Antibodies for Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Monoclonal Antibodies for Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region
  1. 7.1 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region
  2. 7.1.1 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region (2021-2026)
  4. 7.1.3 Global Monoclonal Antibodies for Plaque Psoriasis Revenue by Region (2027-2032)
  5. 7.1.4 Global Monoclonal Antibodies for Plaque Psoriasis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Monoclonal Antibodies for Plaque Psoriasis Revenue (2021-2032)
  8. 7.2.2 North America Monoclonal Antibodies for Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Monoclonal Antibodies for Plaque Psoriasis Revenue (2021-2032)
  11. 7.3.2 Europe Monoclonal Antibodies for Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Monoclonal Antibodies for Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie, Inc.
  2. 8.1.1 AbbVie, Inc. Company Information
  3. 8.1.2 AbbVie, Inc. Business Overview
  4. 8.1.3 AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  6. 8.1.5 AbbVie, Inc. Recent Developments
  7. 8.2 Almirall SA
  8. 8.2.1 Almirall SA Company Information
  9. 8.2.2 Almirall SA Business Overview
  10. 8.2.3 Almirall SA Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Almirall SA Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  12. 8.2.5 Almirall SA Recent Developments
  13. 8.3 Bausch Health Cos., Inc
  14. 8.3.1 Bausch Health Cos., Inc Company Information
  15. 8.3.2 Bausch Health Cos., Inc Business Overview
  16. 8.3.3 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bausch Health Cos., Inc Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  18. 8.3.5 Bausch Health Cos., Inc Recent Developments
  19. 8.4 Biocon Ltd.
  20. 8.4.1 Biocon Ltd. Company Information
  21. 8.4.2 Biocon Ltd. Business Overview
  22. 8.4.3 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Biocon Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  24. 8.4.5 Biocon Ltd. Recent Developments
  25. 8.5 Janssen Biotech, Inc.
  26. 8.5.1 Janssen Biotech, Inc. Company Information
  27. 8.5.2 Janssen Biotech, Inc. Business Overview
  28. 8.5.3 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Janssen Biotech, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  30. 8.5.5 Janssen Biotech, Inc. Recent Developments
  31. 8.6 Sun Pharmaceutical Industries Ltd.
  32. 8.6.1 Sun Pharmaceutical Industries Ltd. Company Information
  33. 8.6.2 Sun Pharmaceutical Industries Ltd. Business Overview
  34. 8.6.3 Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sun Pharmaceutical Industries Ltd. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  36. 8.6.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  37. 8.7 UCB, Inc.
  38. 8.7.1 UCB, Inc. Company Information
  39. 8.7.2 UCB, Inc. Business Overview
  40. 8.7.3 UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 UCB, Inc. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  42. 8.7.5 UCB, Inc. Recent Developments
  43. 8.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd
  44. 8.8.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd Company Information
  45. 8.8.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd Business Overview
  46. 8.8.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  48. 8.8.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments
  49. 8.9 Eli Lilly & Co.
  50. 8.9.1 Eli Lilly & Co. Company Information
  51. 8.9.2 Eli Lilly & Co. Business Overview
  52. 8.9.3 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly & Co. Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  54. 8.9.5 Eli Lilly & Co. Recent Developments
  55. 8.10 Novartis AG
  56. 8.10.1 Novartis AG Company Information
  57. 8.10.2 Novartis AG Business Overview
  58. 8.10.3 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis AG Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  60. 8.10.5 Novartis AG Recent Developments
  61. 8.11 Chongqing Genrix Biopharmaceutical Co., Ltd
  62. 8.11.1 Chongqing Genrix Biopharmaceutical Co., Ltd Company Information
  63. 8.11.2 Chongqing Genrix Biopharmaceutical Co., Ltd Business Overview
  64. 8.11.3 Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Chongqing Genrix Biopharmaceutical Co., Ltd Monoclonal Antibodies for Plaque Psoriasis Product Portfolio
  66. 8.11.5 Chongqing Genrix Biopharmaceutical Co., Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Monoclonal Antibodies for Plaque Psoriasis Value Chain Analysis
  2. 9.1.1 Monoclonal Antibodies for Plaque Psoriasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Monoclonal Antibodies for Plaque Psoriasis Production Mode & Process
  6. 9.2 Monoclonal Antibodies for Plaque Psoriasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Monoclonal Antibodies for Plaque Psoriasis Distributors
  9. 9.2.3 Monoclonal Antibodies for Plaque Psoriasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst